ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA"

  • Abstract Number: 2729 • 2018 ACR/ARHP Annual Meeting

    Increased Risk of Cerebrovascular Accident Among Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review and Meta-Analysis of Cohort Studies

    Patompong Ungprasert1, Karn Wijarnpreecha2 and Wisit Cheungpasitporn3, 1Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, 2Internal medicine, Bassett medical center, cooperstown, NY, 3Medicine, University of Mississippi Medical center, Jackson, MS

    Increased Risk of Cerebrovascular Accident among Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Systematic Review and Meta-analysis of Cohort StudiesAbstractBackground/Purpose: An increased risk of cardiovascular…
  • Abstract Number: 13 • 2018 ACR/ARHP Annual Meeting

    Shared Genetic Origins Among Anti-Proteinase 3 and Anti-Glomerular Basement Membrane Double-Positive Human Autoantibodies

    Jeffrey R. Ord1, Amy G. Clark1 and Mary H. Foster2, 1Duke University Medical Center, Durham, NC, 2Medicine, Duke University Medical Center, Durham, NC

    Background/Purpose: Patients with ANCA vasculitis and anti-glomerular basement membrane (GBM) nephritis (Goodpasture’s Disease) develop pathogenic autoantibodies (autoAb) that destroy the microvasculature in lungs and kidneys.…
  • Abstract Number: 1764 • 2018 ACR/ARHP Annual Meeting

    The Utility of Serum Angiopoietin-1 and Angiopoietin-2 in Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis

    Yoko Wada1, Takeshi Kuroda2, Masaaki Nakano3 and Ichiei Narita1, 1Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Health Administration Center, Niigata University, Niigata, Japan, 3Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan

    Background/Purpose: Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) are antagonistic ligands which bind with similar affinity to the extracellular domain of the tyrosine kinase with Ig-like and…
  • Abstract Number: 2731 • 2018 ACR/ARHP Annual Meeting

    Clinical Characteristics and Outcomes of ANCA-Vasculitides Associated Renal Disease in a Multi-Ethnic Population from a County Hospital

    Shilpa Arora1, Ambrish Athavale2 and Peter Hart2, 1Medicine, John H Jr Stroger Hospital of Cook County, Chicago, IL, 2John H Jr Stroger Hospital of Cook County, Chicago, IL

    Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal-limited vasculitis (RLV). We aimed to study the clinical features…
  • Abstract Number: 904 • 2018 ACR/ARHP Annual Meeting

    Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry

    John L. Niles1, Peter A. Merkel2, Lester Mertz3, Patricia B. Lehane4, Pooneh Pordeli5 and Félix Erblang6, 1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, 2Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Roche Products Ltd., Welwyn Garden City, United Kingdom, 5Hoffmann-La Roche Ltd., Mississauga, ON, Canada, 6Hoffmann-La Roche Ltd., Basel, Switzerland

    Background/Purpose: Potential therapy-related toxicities are important causes of morbidity in patients with the ANCA-associated vasculitides granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). Long-term safety…
  • Abstract Number: 1765 • 2018 ACR/ARHP Annual Meeting

    Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis

    Yasuhiro Shimojima1, Dai Kishida2 and Yoshiki Sekijima2, 1Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, 2Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan

    Background/Purpose: Hypertrophic pachymeningitis (HP), which becomes the cause of chronic headache, seizure, and cranial neuropathy, is an inflammatory disorder demonstrating focal and diffuse thickening of…
  • Abstract Number: 2732 • 2018 ACR/ARHP Annual Meeting

    Peripheral Neuropathy Is More Common in Microscopic Polyangiitis Than in Granulomatosis with Polyangiitis: Data from a Single Tertiary Referral Center

    Mehmet Nedim Taş1, Mete Kara1, Sertaç Ketenci1, Mete Pekdiker2, Raika Durusoy3, Fikret Bademkıran4, Gokhan Keser5 and Kenan Aksu5, 1Rheumatology, Ege University Medical Faculty, izmir, Turkey, 2Adult Rheumatology, Ege University Medical Faculty, izmir, Turkey, 3Public Health, Ege University Medical Faculty, izmir, Turkey, 4Neurology, Ege University Medical Faculty, izmir, Turkey, 5Rheumatology, Ege University Medical Faculty, Izmir, Turkey

    Background/Purpose: Among many other organs and systems, ANCA-associated vasculitis (AAV) may also affect nervous system in up to more than half of patients, resulting in…
  • Abstract Number: 905 • 2018 ACR/ARHP Annual Meeting

    Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

    Alvise Berti1, Roscoe Warner2, Kent Johnson3, Divi Cornec4, Darrell Schroeder5, Brian Kabat5, Carol Langford6, Gary S. Hoffman7, Cees G.M. Kallenberg8, Philip Seo9, Robert F. Spiera10, Eugene William St. Clair11, Fernando Fervenza12, John H. Stone13, Paul A. Monach14, Ulrich Specks15 and Peter A. Merkel16, 1Pulmonary and Critical Care, Mayo Clinic College of Medicine, Rochester, MN, 2University of Michigan Medical School, Ann Arbor,, MI, 3University of Michigan Medical School, Ann Arbor, MI, 4Rheumatology and UMR1227, Lymphocytes B et Autoimmunité, CHU Brest, Brest, France, 5Mayo Clinic, Rochester, MN, 6Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 7Rheumatology, Cleveland Clinic, Cleveland, OH, 8Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 9Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 10Hospital for Special Surgery, New York, NY, 11Medicine, Duke University Medical Center, Durham, NC, 12Nephrology, Mayo Clinic, Rochester, MN, 13Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, 14Section of Rheumatology, Boston University School of Medicine, Boston, MA, 15Mayo Clinic College of Medicine, Rochester, MN, 16Division of Rheumatology and the Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: The deregulated overproduction of interleukin (IL)-6 has been implicated in several inflammatory and antibody-mediated autoimmune diseases. We aimed to investigate serum IL-6 levels (sIL-6)…
  • Abstract Number: 1767 • 2018 ACR/ARHP Annual Meeting

    Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis

    Vanessa L. Kronzer1, Daniel Larson2, Cynthia S. Crowson3,4, Kenneth J. Warrington5, Steven R. Ytterberg5, Ashima Makol4 and Matthew J. Koster4, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Pathology, Mayo Clinic, Rochester, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Rheumatology, Mayo Clinic, Rochester, MN, 5Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: This study aimed to characterize the presenting features and outcomes of patients with small- or medium-vessel vasculitis and gastrointestinal perforation. Methods: Using a retrospective…
  • Abstract Number: 2733 • 2018 ACR/ARHP Annual Meeting

    From a Myth to a Menace: Increased Disease Severity and Poor Outcomes in an Urban Cohort of African-American Patients with ANCA-Associat­ed Vasculitis

    Kathleen Maksimowicz-McKinnon1, Philip McCarthy2, Sandeep Soman3 and John McKinnon3, 1Rheumatology, Henry Ford Hospital, Detroit, MI, 2Michigan State University College of Osteopathic Medicine, East Lansing, MI, 3Henry Ford Hospital, Detroit, MI

    Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is a systemic inflammatory disorder frequently associated with significant disability and morbidity, which may lead to end-stage renal disease…
  • Abstract Number: 906 • 2018 ACR/ARHP Annual Meeting

    Defining the Gut Microbiome in Patients with ANCA-Associated Vasculitis

    Catherine E. Najem1, Jung-Jin Lee2, Ceylan Tanes2, Antoine G. Sreih1, Rennie L. Rhee1, Abdallah Geara3, Hongzhe Li4, Kyle Bittinger2, James D. Lewis5 and Peter A. Merkel4,6, 1Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, 3Division of Nephrology and Hypertension, University of Pennsylvania, Philadelphia, PA, 4Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, 5Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, 6Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose:Although a link between gut microbiome and autoimmune diseases has been suggested, there is a gap in the understanding of the gut microbiome in ANCA-associated…
  • Abstract Number: 1768 • 2018 ACR/ARHP Annual Meeting

    Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis

    Takamasa Murosaki, Takeo Sato, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan

    Background/Purpose: The use of immunosuppressant (IS) with glucocorticoid is recommended as remission induction treatment for severe cases with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).…
  • Abstract Number: 2734 • 2018 ACR/ARHP Annual Meeting

    The Effect of Age at Diagnosis on Mortality in ANCA-Associated Vasculitides

    Mete Kara1, Mehmet Nedim Taş1, Raika Durusoy2, Sertaç Ketenci1, Mete Pekdiker3, Hande Ece Öz4, Gülay Aşçı5, Gokhan Keser6 and Kenan Aksu4, 1Rheumatology, Ege University Medical Faculty, izmir, Turkey, 2Public Health, Ege University Medical Faculty, izmir, Turkey, 3Adult Rheumatology, Ege University Medical Faculty, izmir, Turkey, 4Rheumatology, Ege University Medical Faculty, İzmir, Turkey, 5Nephrology, Ege University Medical Faculty, İzmir, Turkey, 6Rheumatology, Ege University Medical Faculty, Izmir, Turkey

    Background/Purpose: Elderly patients with ANCA associated vasculitides (AAV) seem to have clinical differences compared to younger patients. The aim of this study is to compare…
  • Abstract Number: 907 • 2018 ACR/ARHP Annual Meeting

    Characterization of Preferential Recognition of a Chimeric Recombinant Proteinase 3 Variant By Anti-Neutrophil Cytoplasmic Antibodies

    Gwen Thompson1, Marta Casal Moura2, Darlene Nelson1, Amber Hummel1, Dieter E. Jenne3, Fernando Fervenza4, Gary S. Hoffman5, Cees G.M. Kallenberg6, Carol Langford7, Joseph W. McCune8, Peter A. Merkel9, Paul A. Monach10, Philip Seo11, Robert F. Spiera12, Eugene William St. Clair13, Steven R. Ytterberg14, John H. Stone15, William H. Robinson16, Yuan-Ping Pang1 and Ulrich Specks17, 1Mayo Clinic, Rochester, MN, 2Pulmonary and Critical Care, Thoracic Disease Research Unit, Mayo Clinic College of Medicine, Rochester, MN, 3Helmholtz Zentrum München, Munich, Germany, 4Nephrology, Mayo Clinic, Rochester, MN, 5Rheumatology, Cleveland Clinic, Cleveland, OH, 6University of Gronigen, Groningen, Netherlands, 7Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 8University of Michigan, Ann Arbor, MI, 9University of Pennsylvania, Philadelphia, PA, 10Section of Rheumatology, Boston University School of Medicine, Boston, MA, 11Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, 12Hospital for Special Surgery, New York, NY, 13Medicine, Duke University Medical Center, Durham, NC, 14Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 15Rheumatology (Medicine), Massachusetts General Hospital, Harvard Medical School, Boston, MA, 16Stanford, Stanford, CA, 17Mayo Clinic College of Medicine, Rochester, MN

    Background/Purpose: Human-murine chimeric variants have been used to study specific epitope recognition by anti-neutrophil cytoplasmic antibodies (ANCAs) targeting proteinase 3 (PR3) in patients with ANCA-associated…
  • Abstract Number: 1958 • 2018 ACR/ARHP Annual Meeting

    Gene Expression Pathways across Multiple Tissues in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Reveal Core Pathways of Disease Pathology

    Marcia Friedman1, Donseok Choi1,2,3,4, Steven Planck1,4, James T. Rosenbaum5 and Cailin Sibley1, 1Oregon Health & Science University, Portland, OR, 2OHSU-PSU School of Public Health, Portland, OR, 3Graduate School of Dentistry, Kyung Hee Universtiy, Seoul, Korea, Republic of (South), 4Casey Eye Institute, Portland, OR, 5Ophthalmology, Oregon Health & Science University and Legacy Devers Eye Institute, Portland, OR

    Background/Purpose: In recent years, several studies have characterized the gene expression signatures of different tissues affected by ANCA-associated vasculitis (AAV). The purpose of this study…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology